Pharmacogenetics in Africa, an Opportunity for Appropriate Drug Dosage Regimens: on the Road to Personalized Healthcare

被引:13
作者
Masimirembwa, C. [1 ]
Hasler, J. A. [1 ]
机构
[1] African Inst Biomed Sci & Technol, Harare, Zimbabwe
关键词
D O I
10.1038/psp.2013.17
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The modern human appeared in Africa around 200,000 years ago with subsequent later migrations to populate Europe, Asia, and North America. 1 As humans adapted to various diets, diseases, climates, and so on, inherited traits emerged that gave rise to distinct population groups with physical and physiological differences, including the response to xenobiotic challenges (Figure 1). This Perspective highlights the interpopulation differences in response to drugs focusing on Africa and implications for global pharmacometric studies.
引用
收藏
页数:4
相关论文
共 10 条
[1]  
Azuma J., 2012, EUR J CLIN PHARM
[2]   African genetic diversity: Implications for human demographic history, modern human origins, and complex disease mapping [J].
Campbell, Michael C. ;
Tishkoff, Sarah A. .
ANNUAL REVIEW OF GENOMICS AND HUMAN GENETICS, 2008, 9 :403-433
[3]   The SLCO1B1 rs4149032 Polymorphism Is Highly Prevalent in South Africans and Is Associated with Reduced Rifampin Concentrations: Dosing Implications [J].
Chigutsa, Emmanuel ;
Visser, Marianne E. ;
Swart, Elizabeth C. ;
Denti, Paolo ;
Pushpakom, Sudeep ;
Egan, Deirdre ;
Holford, Nicholas H. G. ;
Smith, Peter J. ;
Maartens, Gary ;
Owen, Andrew ;
McIlleron, Helen .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (09) :4122-4127
[4]   Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms [J].
Daly, Ann K. .
ARCHIVES OF TOXICOLOGY, 2013, 87 (03) :407-420
[5]   A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: Association with diminished debrisoquine hydroxylase activity [J].
Masimirembwa, C ;
Persson, I ;
Bertilsson, L ;
Hasler, J ;
IngelmanSundberg, M .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 42 (06) :713-719
[6]   Establishment of a biobank and pharmacogenetics database of African populations [J].
Matimba, Alice ;
Oluka, Margaret N. ;
Ebeshi, Benjamin U. ;
Sayi, Jane ;
Bolaji, Oluseye O. ;
Guantai, Anastasia N. ;
Masimirembwa, Collen M. .
EUROPEAN JOURNAL OF HUMAN GENETICS, 2008, 16 (07) :780-783
[7]   Pharmacogenetics - five decades of therapeutic lessons from genetic diversity [J].
Meyer, UA .
NATURE REVIEWS GENETICS, 2004, 5 (09) :669-676
[8]   Impact of gender, weight and CYP2B6 genotype on efavirenz exposure in patients on HIV/AIDS and TB treatment: Implications for individualising therapy [J].
Nemaura, Tafireyi ;
Nhachi, Charles ;
Masimirembwa, Collen .
AFRICAN JOURNAL OF PHARMACY AND PHARMACOLOGY, 2012, 6 (29) :2188-2193
[9]   High prevalence of the CYP2B6 516G→T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe [J].
Nyakutira, Christopher ;
Roshammar, Daniel ;
Chigutsa, Emmanuel ;
Chonzi, Prosper ;
Ashton, Michael ;
Nhachi, Charles ;
Masimirembwa, Collen .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 64 (04) :357-365
[10]   CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network [J].
Relling, M. V. ;
Klein, T. E. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 (03) :464-467